India Inc India Inc: Thursday, 12 January 2017 07:38

Lupin to sell skin cream in US



Indian drug major Lupin has received final approval from the US health regulator to market its Desoximetasone cream, used for treatment of skin disease, in the US market.

Lupin said in a Bombay Stock Exchange (BSE) filing that it “has received final approval for its Desoximetasone cream USP, 0.05 per cent and Desoximetasone cream USP, 0.25 per cent from the United States Food and Drug Administration (USFDA).”

The products to be marketed are generic versions of Taro’s Topicort LP Emollient cream, 0.05 per cent and Topicort cream, 0.25 per cent.

As per IMS MAT September 2016 data, Topicort LP emollient cream had US sales of $33 million while Topicort cream had US sales of $17 million, Lupin said.

“Both products are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses,” it added.

India Global Business’ has been tracking this issue

Login to post comment
Get in Touch
This email address is being protected from spambots. You need JavaScript enabled to view it.

Array ( [format] => html [Itemid] => 148 [option] => com_k2 [view] => item [task] => 6415:lupin-to-sell-skin-cream-in-us [id] => 6415:lupin-to-sell-skin-cream-in-us )